Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

CBD oil shows promise for easing anxiety and depression in Parkinson's patients

NCT ID NCT07651930

Symptom relief Sponsor: Medical University of Warsaw Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tested whether full-spectrum CBD oil can help with anxiety and depression in people with Parkinson's disease. Twenty-seven participants took one of three daily doses (30, 60, or 300 mg) for two months. Researchers measured changes in anxiety and depression scores, along with sleep, fatigue, and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
full-spectrum cannabidiol (CBD) oil
What this could lead to
If it works, this could point toward a safe, natural supplement to ease anxiety and depression in people with Parkinson's disease.
What could go wrong
This is a small, early-phase trial with only 27 participants. The results may not apply to everyone, and CBD can cause side effects like drowsiness or stomach issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

27 people

The number who actually took part.

Started

Dec 2023

Finished

Nov 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosed Parkinson's Disease according to MDS Clinical Diagnostic Criteria (2015). * Disease duration ≥4 years before study inclusion. * Age between 40 and 70 years at enrollment. * Stable oral medication regimen (including Parkinson's disease medications, antidepressants, and anxiolytics) for at least 1 month prior to inclusion and maintained throughout the study (up to 2 months from inclusion). * Moderate or higher anxiety-depressive symptoms at baseline (BDI ≥11 points, BAI ≥16 points) Exclusion Criteria: * Dementia or cognitive impairment. * Advanced Parkinson's therapy (DBS, infusion pumps, ablation) or planned initiation within study duration (2 months). * No caregiver support. * Pregnancy, breastfeeding, or lack of contraception in women of childbearing potential. * Neurological or psychiatric disorders affecting evaluation (vascular CNS damage, previous CNS surgery). * Musculoskeletal conditions preventing motor assessments. * Active malignancy. * Cannabinoids use within the last 30 days. * Use of hepatotoxic drugs or drugs with potential toxic interaction with CBD (e.g., valproic acid, warfarin, haloperidol) within 90 days prior to inclusion. * Paracetamol intake exceeding 1 g/day during study participation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Parkinson'S disease (PD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anxiety disorder Depression Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Parkinson'S disease (PD)

Contacts and locations

Locations

  • Department of Neurology, Faculty of Health Sciences, Medical University of Warsaw

    Warsaw, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.